REL-1017 (Esmethadone), A Novel NMDAR Blocker for the Treatment of MDD is Not Neurotoxic in Sprague-Dawley Rats.

Bifari, Francesco; Pappagallo, Marco; Bleavins, Michael; Traversa, Sergio; Folli, Franco; Manfredi, Paolo L

Bifari, Francesco; Pappagallo, Marco; Bleavins, Michael; Traversa, Sergio; Folli, Franco; Manfredi, Paolo L.

Afiliación

Bifari F; Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.
Pappagallo M; Relmada Therapeutics, Coral Gables, FL, United States.
Bleavins M; Environmental Health Sciences and School of Public Health, University of Michigan, Ann Arbor, MI, United States.
Traversa S; Relmada Therapeutics, Coral Gables, FL, United States.
Folli F; Department of Health Sciences, University of Milano, Milan, Italy.
Manfredi PL; Relmada Therapeutics, Coral Gables, FL, United States.

Front Pharmacol ; 13: 863959, 2022.

Article en En | MEDLINE | ID: mdl-35571103

Palabras clave

N-methyl-D-aspartate receptor channel blocker; Olney's lesion; REL-1017; esmethadone; neurotoxic

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Front Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: Italia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google